J. David Owens
President & CEO
Rob Gensure, MD, PhD
Chief Medical Officer
Robyn Goforth, PhD
Chief Scientific Officer
For more information about
BiologicsMD, please contact:
BiologicsMD is an early stage therapeutic development company focused on developing highly-targeted or ‘smart’ therapies for the treatment of severe bone disorders and hair loss related diseases and conditions. The company is developing a series of recombinant fusion proteins that provide powerful osteogenic and anabolic effects directly to the target receptors at the point of disease – and do so with sustained therapeutic exposure in either a single dose or very infrequent dosing regimens. The company is working on formulation and delivery vehicles that can accommodate parenteral, local, and topical administration.
Technology and Therapeutic Focus
BiologicsMD’s core technology consists of the manufacturing and development of recombinant fusion proteins. The first protein, PTH-CBD™, is the fusion of the active domain of parathyroid hormone (amino acids 1-33) coupled to a collagen binding domain derived from ColH collagenase. The collagen binding domain (CBD) causes the protein to accumulate in bone tissue. In the bone, the PTH (1-33) domain activates the PTH/PTHrP receptor and increases bone formation.
PEER REVIEWED SCIENTIFIC PUBLICATIONS
PTH-CBD™ is being developed for the treatment of severe bone disorders with acute fracture repair as the initial target indication.
BiologicsMD has a second compound and program that is focused on the prevention of hair loss and restoration of hair that results from various forms of alopecia.